文献速递骨软组织肉瘤与黑色素瘤

MEK抑制剂tunlametinib治疗晚期NRAS突变黑色素瘤疗效与安全性的II期研究

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
PubMed 文献 · Eur J Cancer · 2024-03-11

这项多中心、单臂、II期关键注册研究评估了MEK抑制剂tunlametinib在不可切除III/IV期NRAS突变黑色素瘤患者中的疗效与安全性,共入组100例患者。独立影像评审委员会评估的客观缓解率为35.8%,中位缓解持续时间6.1个月,中位无进展生存期4.2个月,中位总生存期13.7个月,未发生治疗相关死亡。

要点

  • 在95例经中心实验室确认NRAS突变的FAS人群中,IRRC评估的ORR为35.8%,中位DOR为6.1个月。
  • 中位PFS为4.2个月,DCR为72.6%,中位OS为13.7个月,未发生治疗相关死亡。
  • 既往接受过免疫治疗的患者亚组ORR为40.6%。

核心结论

  • tunlametinib在晚期NRAS突变黑色素瘤患者(包括既往接受过免疫治疗者)中显示出有前景的抗肿瘤活性和可控的安全性。
  • 研究结果需要在随机临床试验中进一步验证。

研究设计与样本

  • 多中心、单臂、II期关键注册研究(NCT05217303)。
  • 研究评估MEK抑制剂tunlametinib在不可切除III/IV期NRAS突变黑色素瘤患者中的疗效与安全性。
  • 2020年11月2日至2022年2月11日期间共入组100例患者,全部100例接受至少一剂tunlametinib(安全性分析集),其中95例经中心实验室确认NRAS突变(全分析集FAS)。
  • 主要终点为独立影像评审委员会(IRRC)按RECIST v1.1评估的客观缓解率(ORR)。
  • 次要终点包括无进展生存期(PFS)、疾病控制率(DCR)、缓解持续时间(DOR)、总生存期(OS)和安全性。

主要发现

  • FAS人群中NRAS突变位于Q61者占78.9%,G12者占15.8%,G13者占5.3%。
  • IRRC评估的ORR为35.8%,中位DOR为6.1个月。
  • 中位PFS为4.2个月,DCR为72.6%,中位OS为13.7个月。
  • 既往接受过免疫治疗的患者亚组ORR为40.6%。
  • 未发生治疗相关死亡。

局限性

  • 原文指出研究结果需要在随机临床试验中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: NRAS-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide. METHODS: We conducted a multicenter, single-arm, phase II, pivotal registrational study that evaluated the efficacy and safety of the MEK inhibitor tunlametinib in patients with unresectable, stage III/IV, NRAS-mutant melanoma (NCT05217303). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The secondary endpoints included progression-free survival (PFS), disease control rate (DCR), duration of response(DOR), overall survival (OS) and safety. FINDINGS: Between November 2, 2020 and February 11, 2022, a total of 100 patients were enrolled. All (n = 100) patients received at least one dose of tunlametinib (safety analysis set [SAS]) and 95 had central laboratory-confirmed NRAS mutations (full analysis set [FAS]). In the FAS, NRAS mutations were observed at Q61 (78.9%), G12 (15.8%) and G13 (5.3%). The IRRC-assessed ORR was 35.8%, with a median DOR of 6.1 months. The median PFS was 4.2 months, DCR was 72.6% and median OS was 13.7 months. Subgroup analysis showed that in patients who had previously received immunotherapy, the ORR was 40.6%. No treatment-related deaths occurred. INTERPRETATION: Tunlametinib showed promising antitumor activity with a manageable safety profile in patients with advanced NRAS-mutant melanoma, including those who had prior exposure to immunotherapy. The findings warrant further validation in a randomized clinical trial.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wei X, Zou Z, Zhang W, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. Eur J Cancer. 2024. PMID: 38479118. doi:10.1016/j.ejca.2024.114008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。